Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29255668 | 0.85 | SLC40A1 (0.68) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL30854820 | 0.85 | SLC40A1 (0.68) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL3531084 | 0.81 | HCRTR1 (0.47) | MEN1KMT2ASLC40A1GAAALDH1A1 | |
| SCHEMBL1507919 | 0.80 | SLC40A1 (0.76) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL30854809 | 0.80 | SLC40A1 (0.76) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL3533823 | 0.79 | SLC40A1 (0.55) | SLC40A1 | |
| SCHEMBL29540765 | 0.79 | GAA (0.71) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL22234047 | 0.79 | GAA (0.71) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL30854823 | 0.77 | SLC40A1 (0.70) | ATMMEN1KMT2ASLC40A1GAA | |
| SCHEMBL29255663 | 0.77 | SLC40A1 (0.70) | ATMMEN1KMT2ASLC40A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-1919474-B1 | PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS | FOURNIER LAB SA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | ATM 1546/4885MEN1 4459/4885KMT2A 2834/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | ATM 1675/4885MEN1 4228/4885KMT2A 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.